Based upon the allele frequency of HLA-A*11:01 in the US population and the prevalence of KRASG12V among PAAD, COAD, and LUAD patients, we estimate that A11Va TCR-T therapies could be applicable to more than 5,000 patients per year in the USA (41). The gene discussed is HLA-A; the disease is pancreatic adenocarcinoma.